Anna Koudrina

Anna received her PhD in Chemistry, with specialization in Chemical and Environmental Toxicology from Carleton University in Ottawa, Canada. During her graduate studies, she developed oligonucleotide-based contrast agents for MRI and CT imaging, geared towards more precise diagnosis of conditions that involve blood clots. She then did a postdoctoral fellowship at the University of Massachusetts Medical School, within the RNA Therapeutics Institute, where she was able to shift her focus towards developing oligonucleotide-based therapeutics for neurodevelopmental disorders.

Anna joined the Translational Vectorology Research Unit at CMRI in August 2022 where she continues to work with oligonucleotide therapeutics for management of rare disease indications.”